Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Phil Cressman who wrote (6969)	4/14/1998 10:48:00 AM
From: EyeDrMike	Read Replies (1) \| Respond to of 23519

<<ÿÿIn fixed-dose studies, dyspepsia (17%) and abnormal vision (11%) were more common at 100 mg than at lower doses. At doses above the recommended dose range, adverse events were similar to those detailed above but generally were reported more frequently.>> Phil, respectfully, read the above again. The 2% number comes from "flexible dose trials". In FIXED dose studies 11% had abnormal vision at doses of 100 mg. And in higher dosing, patients will report increased visual abnormalties. I am appalled that the studies did not break down ED by type, or have fixed dosing, or that they used such a large age range. The data, using so many variables, could have been manipulated to achieve any outcome desired. Mike